Flerie AB’s (publ) portfolio company Prokarium has presented positive interim data from the ongoing Phase 1/1b study of its drug candidate ZH9 to treat non-muscle invasive bladder cancer. The drug candidate’s safety profile is considered favourable, and among the patients who completed the study protocol, 91 per cent were recurrence-free after 12 months.
The study results were presented at the American Urological Association’s annual meeting, recently held in Washington D.C., USA. Prokarium’s microbial immunotherapy technology allows physicians to use the same treatment protocol as the current standard of care, but with several potential benefits that are now supported by the interim results.
“Prokarium’s platform technology is very well suited to improving the treatment of bladder cancer, and the company now has strong results to support this. Although the technology is highly innovative, physicians do not need to change the way they treat patients. Now Prokarium has taken a significant step in that direction, which can create great value for both patients and the company's shareholders,” says Ted Fjällman, CEO of Flerie and Chairman of Prokarium.
Read Prokarium’s full press release here: https://www.prokarium.com/news/prokarium-reports-positive-interim-data-from-phase-1-1b-paradigm-1-trial-of-zh9-
Flerie’s ownership in Prokarium amounts to 50%.
For more information:
Ted Fjällman, CEO
Email: ir@flerie.com
About non-muscle invasive bladder cancer (NMIBC)
Bladder cancer is divided into several groups, and Prokarium’s treatment targets NMIBC, which is also the most common form. The standard of care comprises two steps: surgical removal of tumours and immunotherapy. Prokarium’s treatment replaces the latter step and is a simpler treatment with significantly less discomfort for the patient, which leads to better compliance and treatment outcomes. An estimated 1,500,000 patients are living with bladder cancer across Europe and the United States.